Navigation Links
Amicus Therapeutics Board of Directors Names Chief Executive Officer John F. Crowley Chairman of the Board
Date:2/5/2010

CRANBURY, N.J., Feb. 5 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) announced today that its Board of Directors has elected John F. Crowley as Chairman of the Board in addition to his current role as Chief Executive Officer (CEO), effective immediately.  Mr. Crowley will succeed Donald J. Hayden, Jr., who will become the Lead Independent Director of the Board.

"The Board's decision to elect Mr. Crowley as Chairman of the Board reflects our confidence in his leadership and vision for Amicus.  Additionally, the Board recognized the value of the strong independent leadership provided by Mr. Hayden during his tenure as Chairman which will be preserved through his appointment as Lead Independent Director," stated Alexander Barkas, Ph.D., Amicus Board of Director and Member of Governance and Nominating Committee.

In his role as Chairman of the Board, Mr. Crowley will lead the Board's efforts in overseeing the development and implementation of the Company's strategic vision.  

As Lead Independent Director, Mr. Hayden will be responsible for, among other things, leading executive sessions of the Board's independent directors, advising the independent board committee chairs in fulfilling their responsibilities to the Board, assisting the Board and the Company's Officers in complying with Amicus' governance guidelines and overseeing the process of evaluating, developing and compensating the CEO.  A copy of the Lead Independent Director Charter describing in full Mr. Hayden's roles and responsibilities is available on the Amicus website at www.amicustherapeutics.com.

About Amicus Therapeutics

Amicus Therapeutics is developing orally-administered, small molecule drugs called pharmacological chaperones, a novel, first-in-class approach to treating a broad range of diseases including lysosomal storage disorders and diseases of neurodegeneration.  Amicus' lead program is in Phase 3 for the treatment of Fabry disease.

FOLD –G

SOURCE Amicus Therapeutics

RELATED LINKS
http://www.amicustherapeutics.com

'/>"/>

SOURCE Amicus Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... Mass. , Nov. 30, 2016   Merck ... that it has entered into a set of agreements ... services for Merck,s collection of genetic reagents such as ... with Evotec,s screening expertise offers an accelerated pathway to ... discovery starts with the identification of new targets, a ...
(Date:11/30/2016)... ... November 30, 2016 , ... Energetiq Technology, a world leader ... generation, ultra-bright, Laser-Driven Light Source, the EQ-77, at the MRS Fall Exhibit 2016. ... offers higher radiance and irradiance from a truly broadband white light source. The ...
(Date:11/30/2016)... ... November 30, 2016 , ... On 28 November 2016, the International Union ... nihonium (Nh), moscovium (Mc), tennessine (Ts), and oganesson (Og), respectively for element 113, ... earlier proposed by the discoverers have been approved by the IUPAC Bureau. The IUPAC ...
(Date:11/30/2016)... ... November 30, 2016 , ... ... of precision treatments for neurodegenerative diseases, today announced that all five of its ... 3, 2016) blocked propagation of toxic, prion-like forms of Amyloid beta (Aß) in ...
Breaking Biology Technology:
(Date:11/15/2016)... 15, 2016  Synthetic Biologics, Inc. (NYSE MKT: ... on the gut microbiome, today announced the pricing ... of its common stock and warrants to purchase ... price to the public of $1.00 per share ... from the offering, excluding the proceeds, if any ...
(Date:6/27/2016)... 2016 Research and Markets has announced the ... report to their offering. The ... to grow at a CAGR of 12.28% during the period ... an in-depth market analysis with inputs from industry experts. The report ... years. The report also includes a discussion of the key vendors ...
(Date:6/21/2016)... Columbia , June 21, 2016 ... to the new role of principal product architect ... named the director of customer development. Both will ... chief technical officer. The moves reflect NuData,s strategic ... in response to high customer demand and customer ...
Breaking Biology News(10 mins):